A proposed framework for formulary listing in low-income countries: Incorporating key features from established drug benefit plans

Pharmaceutical Medicine

Volumn 25, Issue 2, 2011, Pages 71-82

  Diaby, Vakaramoko ^a   Laurier, Claudine ^a   Lachaine, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cost benefit; Cost containment; Cost effectiveness; Decision analysis; Drug utilisation; Formularies; Legislation; Pharmacoeconomics; Prescribing

Indexed keywords

PRESCRIPTION DRUG;

BRAZIL; CANADA; DEVELOPING COUNTRY; DRUG BENEFIT PLAN; DRUG FORMULARY; DRUG INDUSTRY; DRUG MARKETING; DRUG PROGRAM; FRANCE; GERMANY; GHANA; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; LOWEST INCOME GROUP; MEDICAID; MEDICARE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; REIMBURSEMENT; REVIEW; SOCIAL INSURANCE; SOUTH KOREA; UNITED KINGDOM; UNITED STATES;

EID: 79955124227     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.2165/11590580-000000000-00000     Document Type: Review

References (43)

1. Mechanic D, Rochefort AD. Comparative medical systems. Annu Rev Sociol 1996; 22: 239-70 (Pubitemid 126416255)
2. Anderson OW. The health services continuum in democratic states. Ann Arbor (MI): Health Admin Press, 1989
3. Kirkman-Liff BL.Management without frontiers: health systems convergence leads to health care management convergence. FrontHealth ServManage 1994; 11: 3-48
4. Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010 May; 95 (2-3): 174-84
5. Health Insurance Sort. Health insurance terminology you should know [online]. Available from URL: terms.htm. [Accessed 2007 May 15]
6. Trudel R. Pour un régime d'assurance médicaments équitable et viable: rapport préparé par le comité sur la pertinence et la faisabilité d'un régime universel public d'assurance médicaments au Québec [online]. Available from URL: http://msssa4.msss.gouv.qc.ca/fr/document/publication.nsf/ 961885cb24e4e9fd85256b1e00641a29/d858bba2a48916fb85256b1f006c7078/$FILE/ montmarquette.pdf [Accessed 2007 May 18]
7. Canadian Agency for Drugs and Technology in Health. Procedure for common drug review April 2009 [online]. Available from URL: http://www.cadth.ca/media/ cdr/process/CDR-Procedure-2009April.pdf. [Accessed 2009 May 15]
8. LevinsonW, LaupacisA.Acall for fairness in formulary decisions. Arch Intern Med 2006; 166: 16-8 (Pubitemid 43063837)
9. Sauviat C. La crise chronique du système de santé amé ricain. Revue de l'IRES 2004; 46: 3-46
10. Medicare.gov. The official U.S. Government site for medicare [online]. Available from URL: http://www.medicare.gov/. [Accessed 2007 May 22]
11. The USP Classification System. Background: how does the USP classification system work? [online]. Available from URL: http://aspe.hhs.gov/ health/reports/05/drugformularies/ch3.pdf. [Accessed 2007 May 22]
12. Gencarelli DM. Medicaid prescription drug coverage: state efforts to control costs. NHPF Issue Brief 2003; 790: 1-17
13. Department of Health & Human Services (DHHS), Centers for Medicare & Medicaid Services (CMS). CMS manual system: pub. 100-18 medicare prescription drug benefit manual. Transmittal 2, July 18, 2008 [online]. Available from URL: loads/R2PDBv2.pdf. [Accessed 2009 Apr 25]
14. Frequently asked questions regarding the West Virginia Medicaid Preferred Drug List (PDL) [online]. Available from URL: http://www.dhhr.wv.gov/bms/ Pharmacy/Pages/FAQ.aspx [Accessed 2011 Mar 16]
15. LambertDC.Les systèmes de santé: analyseetévaluation comparée dans les grands pays industriels. Collection Economie Humaine. Paris, Edition du Seuil, 2000
16. Nguyen-Kim L, Or Z, Paris V, et al. Les politiques de prise en charge des médicaments en France, Allemagne et Angleterre. Bulletin d'information en économie de la santé 2005; 99: 1-6
17. International Society for Pharmaco-economics and Outcomes Research. ISPOR global health care systems road map: Germany-Pharmaceutical (updated June 2009) [online] Available from URL: Maps/Germany.asp#1 [Accessed 2009 Apr 25]
18. Ö BIG. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU Member States, 2006 [online]. Available from URL: comm/competition/mergers/studies-reports/oebig.pdf. [Accessed 2009 Apr 25]
19. International Society for Pharmaco-economics and Outcomes Research. ISPOR global health care systems road map: United Kingdom (England and Wales) reimbursement processes (upated October 2008) [online] Available from URL: http://www.ispor.org/HTARoadMaps/UK.asp. [Accessed 2009 April 25]
20. NHS. Single technology appraisals process: guide to the single technology appraisal (STA) process, 2006 [online]. Available from URL: http:// www.nice.org.uk/aboutnice/howwework/devnicetech/ technologyappraisalprocessguides/singletechnologyappraisalsprocess/ single-technology-appraisals-process.jsp?domedia=1&mid=8DE6BB4B-19B9-E0B5- D4171540D2539 51B. [Accessed 2009 April 25]
21. Haute Autorité de la Santé . Commission de la transparence: règlement inté rieur, 22 Juin 2005 [online]. Available from URL: portail/upload/docs/application/pdf/ri-ct-2005-v.04-10-06.pdf. [Accessed2009 Apr 25]
22. Vieira FS. Pharmaceutical assistance in the Brazilian public health care system [in Portuguese]. Rev Panam Salud Publica 2010 Feb; 27 (2): 149-56
23. WHO. Essential medicines [online]. Available from URL: http://www.who.int/medicines/services/essmedicines-def/en/index.html [Accessed 2010 Nov 27]
24. ISPOR. Health Care System and National Health Insurance of South Korea [online]. Available from URL: http://www.ispor.org/news/articles/Oct08/ HCSystemsSKorea.asp. [Accessed 2010 Nov 24]
25. Bae EY, Lee EK. Pharmaco-economic guidelines and their implementation in the positive list system in South Korea. Value Health 2009; 12: 36-41
26. Salisu A, Prinz V. Austrian Centre for Country of Origin and Asylum Research and Documentation: health care in Ghana [online]. Available from URL: http://www.ecoi.net/file-upload/90-1236873017-accord-health-care-in-ghana- 20090312.pdf. [Accessed 2010 Nov 24]
27. Zaney GD. NHIA must timely®ularly review tariffs&medicine list - SNV. The Ghanaian Journal 2010 Jun 7 [online]. Available from URL: http://www.theghanaianjournal.com/2010/06/07/nhia-must-timely-regularly- reviewtariffs-medicine-list-snv/ [Accessed 2011 Mar 2]
28. Seiter A, Gyansa-Lutterodt M, Ghana National Drugs Program. Policy note: the pharmaceutical sector in Ghana. November 2009 [online]. Available from URL: http://docs.google.com/viewer?a=v&q=cache:-gfu-7O5qv0J:apps.who.int/ medicinedocs/documents/s16765e/s16765e. pdf+Pharmaceutical+sector+in+Ghana+%E2%80%93+NHIA+medicine+list+in+Ghana&hl= fr&gl=ca&pid=bl&srcid= ADGEESgZNmml48cyhaK1L4bgIHDvXG4dQNEbF7j7IGy6GjcqdQvC-uLUMQXqsUEQHU- sj5QDyV4N7oapbET8Hs7d7F2UtpjdOl5o0zCxgQ-Ngm8WNeqHFCWs81netrP8m8YJOgfy7A&sig= AHIEtbTL-CHaeDdPiOednp3srqAIthgm6A. [Accessed 2010 Nov 27]
29. Ghana National Drug Policy (2nd ed.) [online]. Available from URL: . who.int/medicinedocs/documents/s16185e/s16185e.pdf [Accessed 2011Mar 16]
30. Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc 2006; 4: 14
31. Baltussen R, Stolk E, Chisholm D, et al. Towards a multicriteria approach for priority setting: an application to Ghana. Health Econ 2006; 15: 689-96 (Pubitemid 44057240)
32. Linkov I, Varghese A, Jamil S, et al. Multicriteria decision analysis: a frameworkfor structuring remedial decisions at contaminated sites. In: Linkov I, Ramadan A, editors. Comparative risk assessment and environmental decision making. Kluwer 2004; 15-54
33. McDaniel C, Gates R, Gates RH, et al. Marketing research essentials. 7th ed. Hoboken (NJ): John Wiley & Sons Inc., 2005
34. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26 (8): 661-77 (Pubitemid 351989058)
35. Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003; 2 (1) 55-64
36. Wiktorowicz ME. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France. J Health Polit Policy Law 2006; 28: 615-58 (Pubitemid 37012992)
37. Sketris IS, Brown M G, Murphy AL. Policy choices for pharmacare: the need to examine benefit design,medication management strategies and evaluation. Healthc Pap 2004; 4: 36-45
38. Lexchin J, Mintzes B. Medicine reimbursement recommendations in Canada, Australia, and Scotland. Am J Manag Care 2008; 14: 581-8
39. Kohler JC. Drug reimbursement policies: an international perspective and synthesis of recent studies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. (C.A.D.T.H.), 2008
40. Dhalla I, Laupacis A. Moving from opacity to transparency in pharmaceutical policy. CMAJ 2008; 178: 428-31 (Pubitemid 351303286)
41. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee: how recommendations are made. Pharmacoeconomics 2003; 21: 285-94 (Pubitemid 36337724)
42. Kapiriri L, Norheim OF. Criteria for priority-setting in health care in Uganda: exploration of stakeholders' values. Bull World Health Organ 2004; 82: 172-9 (Pubitemid 38524322)
43. Wikipedia. Choice modelling [online]. Available fromURL: http://en.wikipedia.org/wiki/Choice-modelling [Accessed 2009 April 18]